SEC Company Response from Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280) (ORIC) — Apr 20, 2020
Oric Pharmaceuticals, Inc. (ORIC) (CIK 0001796280)
Date: April 20, 2020 · CIK: 0001796280 · Accession: 0001193125-20-111496
AI Filing Summary & Sentiment
Reasoning
Referenced dates: March 6, 2020
Letter
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
O: 650.493.9300
F: 650.493.6811
April 20, 2020
Via EDGAR and Overnight Delivery
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Gabor
Ibolya Ignat
Celeste Murphy
Kevin Vaughn
Re: ORIC Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed February 28, 2020
CIK No. 0001796280
Sir/Madam:
On behalf of our client, ORIC Pharmaceuticals, Inc. (“ORIC” or the “Company”), we submit this letter in response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated March 6, 2020, relating to the above referenced Registration Statement on Form S-1 (the “Registration Statement”). We are concurrently filing via EDGAR a revised Registration Statement (the “Revised Registration Statement”).
In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company’s response. Except for page references appearing in the headings and Staff comments below (which are references to the Registration Statement), all page references herein correspond to the Revised Registration Statement.
AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK
PALO ALTO SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE
ORIC Pharmaceuticals, Inc.
April 20, 2020
Page
Form S-1 filed February 28, 2020
Capitalization, page 83
1. Please tell us how you determined the inclusion of the 118,301 shares resulting from the early option exercise in the number of shares issued and outstanding was considered appropriate to arrive to the pro forma, and pro forma as adjusted presentation. You also disclose on page 8 that you expect these shares will be outstanding after the offering. However, it appears from your disclosure elsewhere that these are shares from —the future exercise of options that are not yet vested and therefore not available to be outstanding. Please revise to clarify this apparent inconsistency.
In response to the Staff’s comment, the Company has updated the disclosure on pages 11, 88 and 91 of the Revised Registration Statement.
*****
ORIC Pharmaceuticals, Inc.
April 20, 2020
Page
Please direct any questions regarding the Company’s responses or the revised draft of the Registration Statement to me at (650) 849-3223 or tjeffries@wsgr.com.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI Professional Corporation
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
O: 650.493.9300
F: 650.493.6811
April 20, 2020
Via
EDGAR and Overnight Delivery
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Gabor
Ibolya Ignat
Celeste Murphy
Kevin Vaughn
Re:
ORIC Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed February 28, 2020
CIK No. 0001796280
Sir/Madam:
On behalf of our client, ORIC Pharmaceuticals, Inc. (“ORIC” or the “Company”), we submit this letter in
response to comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated March 6, 2020, relating to the above referenced Registration
Statement on Form S-1 (the “Registration Statement”). We are concurrently filing via EDGAR a revised Registration Statement (the “Revised Registration Statement”).
In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company’s
response. Except for page references appearing in the headings and Staff comments below (which are references to the Registration Statement), all page references herein correspond to the Revised Registration Statement.
AUSTIN
BEIJING BOSTON BRUSSELS
HONG KONG LONDON LOS ANGELES
NEW YORK
PALO
ALTO SAN DIEGO SAN FRANCISCO
SEATTLE SHANGHAI WASHINGTON, DC
WILMINGTON, DE
ORIC Pharmaceuticals, Inc.
April 20, 2020
Page
2
Form S-1 filed February 28, 2020
Capitalization, page 83
1.
Please tell us how you determined the inclusion of the 118,301 shares resulting from the early option
exercise in the number of shares issued and outstanding was considered appropriate to arrive to the pro forma, and pro forma as adjusted presentation. You also disclose on page 8 that you expect these shares will be outstanding after the offering.
However, it appears from your disclosure elsewhere that these are shares from —the future exercise of options that are not yet vested and therefore not available to be outstanding. Please revise to clarify this apparent inconsistency.
In response to the Staff’s comment, the Company has updated the disclosure on pages 11, 88 and 91 of
the Revised Registration Statement.
*****
ORIC Pharmaceuticals, Inc.
April 20, 2020
Page
3
Please direct any questions regarding the Company’s responses or the revised draft of
the Registration Statement to me at (650) 849-3223 or tjeffries@wsgr.com.
Sincerely,
WILSON SONSINI GOODRICH & ROSATI Professional Corporation
/s/ Tony Jeffries
Tony Jeffries
cc:
Jacob Chacko, ORIC Pharmaceuticals, Inc.
Dominic Piscitelli, ORIC Pharmaceuticals, Inc.
Kenneth Clark, Wilson Sonsini Goodrich & Rosati, P.C.
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.
Melissa Rick, Wilson Sonsini Goodrich & Rosati, P.C.
Charles Kim, Cooley LLP